8 November 2024 - Merck announced that Canada's Drug Agency has recommended Winrevair (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension therapy for the treatment of adults with World Health Organization group 1 PAH and functional class II or III.

Sotatercept is the first activin signalling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signalling to modulate vascular proliferation in pulmonary arterial hypertension patients.

Read Merck press release